Navigation Links
Dr. Reddy's To Launch 'Polypill' For Treating Heart Disease

Indian pharma major Dr. Reddy's Laboratories will launch a first-of-its-kind pill to tackle heart diseases in the second half of 2007, it was announced Thursday. //

The company has teamed up with researchers at University of Auckland, New Zealand, for trials of the groundbreaking 'polypill' that combines four medicines including aspirin and statin, commonly used to treat heart ailments.

India records nearly 2.8 million deaths a year due to cardio-vascular diseases.

'Trials in India are underway. We are conducting trials on 220 patients and after testing on 440 more cases, the product will be launched in the Indian market,' said Satish Reddy, managing director of Dr. Reddy's Lab.

'We have already received the necessary approval from the government for conducting the trails. We hope the product will be available to masses in the second quarter of 2007,' he told reporters at the New Zealand High Commission here.

'This is first-of-its-kind drug in the world to tackle heart problem and will open newer vistas to handle such ailments,' Reddy told IANS, adding it will cost Rs.100 for 30 tablets.

New Zealand's High Commissioner to India Graeme Waters said: 'This project holds open the possibility of revolutionising an important aspect of healthcare in both developing and developed countries.'

The new drug will be cheaper to administer and more effective in preventing strokes and heart attacks, said Anthony Rodgers, a researcher at Auckland University.

The trial aims to confirm that the polypill is effective in lowering cholesterol and blood pressure - known causes of heart attacks and strokes.

The Health Research Council of New Zealand invested NZ$350,000 to support the overall co-ordination of the trial and recruitment in New Zealand. Dr. Reddy's will invest NZ$ 7.5 million in developing the polypill and providing supplies for clinical trials globally.

Source- IANS
'"/>




Related medicine news :

1. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
2. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
3. Dr. Reddys To Invest $100 Mn In Andhra
4. Dr Reddys Eyeing for Generics Arm of Merck
5. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
6. Nutrient Profiling System Launched By Food Officials in UK
7. New Oat And Soy-Based Fat Replacer Launched
8. Launch Of India’s First Virology Course At Pun
9. Race Based Genome Project Launched By Mexico
10. Bird flu In Indonesia: Government To Launch ‘Village Preparedness’ Schee
11. Action Plan Against Drug Deaths Launched
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... April 28, 2017 , ... The National Campaign ... for the Access to Contraception for Women Servicemembers and Dependents Act of 2017. ... (D-CA), will help to ensure that all members of the Armed Forces receive ...
(Date:4/28/2017)... ... , ... It's not always common knowledge whether or not a certain sickness ... to whether or not they are contagious, and most people don't know the answer ... took a look into the matter. , They discovered that the main reason ...
(Date:4/28/2017)... UT (PRWEB) , ... April 28, 2017 , ... Beginning ... some of their formulas. This begins with the popular ClearLungs Extra Strength formula. To ... be changing the formula in the following ways:, , Removal ...
(Date:4/28/2017)... ... April 28, 2017 , ... Getting enough sleep affects much more than energy – it ... 19 hours without sleep can compromise motor reaction time, which can increase the risk of ... is sharing the following tips from the NSF to help you sleep better and feel ...
(Date:4/28/2017)... ... April 28, 2017 , ... Date aired: April ... “Computers are everywhere and they’re here to stay,” said Sharon Kleyne on her ... Your Health on Voice America sponsored by Nature’s Tears® EyeMist®. So she was ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)... 2017 The Global Effective Microorganisms (EM) ... report has covered and analysed the potential of Global Effective ... size, shares and growth factors. The report identifies and analyses ... in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, spread ...
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
Breaking Medicine Technology: